Lumos Pharma Inc expected to post a loss of 93 cents a share - Earnings Preview

Lumos Pharma

27/02/2023 23:13

* Lumos Pharma Inc  LUMO.OQ   LUMO.O  is expected to show a
fall
in quarterly revenue when it reports  results on March 1. 
    * The Austin Texas-based  company is expected to report  a
48.0% decrease in revenue to $114.33 thousand from $220 thousand
a year ago, according to the mean estimate from 6 analysts,
based on Refinitiv data. 
    * ​Refinitiv's mean analyst estimate for Lumos Pharma Inc is
for a
loss of 93 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 5 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Lumos
Pharma Inc
is $21.5​, above​ its last closing price of $3.27. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Sep. 30 2022  -1.00       -1.01      -0.86     Beat    14.7
 Jun. 30 2022  -0.98       -0.99      -0.94     Beat    4.6
 Mar. 31 2022  -0.89       -0.89      -0.92     Missed  -3.1​
 Dec. 31 2021              -0.92      -0.67     Beat    27
 ​​Sep.        -1.07       -1.07      -0.90     Beat    16
 30 2021                                                
 Jun. 30 2021  -1.05       -1.03      -1.04     Missed  -0.6​
 Mar. 31 2021  -0.88       -0.87      -1.04     Missed  -19
 Dec. 31 2020  -0.86       -0.86      -0.31     Beat    64
 This summary was machine generated February 27 at 23:13 GMT. 
All figures in US dollars  unless otherwise stated